-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Verrica Pharmaceuticals Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2017 to Q4 2023.
- Verrica Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2023 was -$24.6M, a 317% decline year-over-year.
- Verrica Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2023 was -$67M, a 174% decline year-over-year.
- Verrica Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$67M, a 174% decline from 2022.
- Verrica Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$24.5M, a 30.3% increase from 2021.
- Verrica Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$35.1M, a 17.8% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)